 |
|
Improving Surveillance for Antimalarial Drug Resistance
Jean-Paul Chretien, MD, PhD;
Mark Fukuda, MD, MPH;
Harald Noedl, MD, PhD, MCTM
JAMA. 2007;297(20):2278-2281.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Global malaria control efforts depend increasingly on artemisinin derivatives because of resistance to other antimalarial drugs. Emergence of artemisinin resistance could be devastating for individuals with malaria, unless timely detection by surveillance systems allows evaluation of new treatments and interventions to counter the spread of resistance. However, instead of drug resistance monitoring, major sponsors of malaria control programs emphasize other essential antimalarial strategies far more strongly.
These sponsors understandably seek immediate public health results with proven antimalarial interventions, but rapid and widespread deployment of artemisinin derivatives, with insufficient attention to drug resistance, could undermine these gains. Developing an early warning system for resistance to artemisinin and other antimalarial drugs should be an urgent priority of malaria control programs and their sponsors.
The Promise of Artemisinin Derivatives
Artemisinin-based combination therapy (ACT), a regimen of artemisinin derivatives taken with other antimalarial drugs to impede . . . [Full Text of this Article]
Author Affiliations: US Department of Defense Global Emerging Infections Surveillance & Response System, Silver Spring, Md (Dr Chretien); Department of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand (Drs Fukuda and Noedl); and Department of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria (Dr Noedl).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Malaria 2007--Progressing Research, Persisting Challenges
Zuccotti and DeAngelis
JAMA 2007;297:2285-2286.
FULL TEXT
|
